A Phase 3 interventional study of Placebo and Belimumab 200 mg SC in Systemic Lupus Erythematosus, sponsored by Human Genome Sciences Inc., a GSK Company. Completed at 207 sites in 31 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-06-06.
Sponsored by Human Genome Sciences Inc., a GSK Company (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing belimumab in Lupus Erythematosus, Systemic — 4 open to participants now, 7 under way, none of them phase 3. belimumab · Lupus Erythematosus, Systemic.
Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, this one is the 3rd largest by enrollment, is one of 3 that started in 2011, is one of 11 in phase 3, and was the 11th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →4 of the 36 studies testing belimumab in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Nanjing University School of Medicine · Sites in China
Ages 14–65
National University Hospital, Singapore · Sites in Singapore
Ages 21–70
First Affiliated Hospital Xi'an Jiaotong University
Ages 18+
By country, each count listing its studies:
belimumab: first FDA approval 2011 (BENLYSTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 839 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 81 across the 36 interventional studies. Of the 27 that completed or were terminated, 20 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under Human Genome Sciences Inc., a GSK Company, one of the names counted as GlaxoSmithKline. Under that name alone:
Human Genome Sciences Inc., a GSK Company is the lead sponsor of 13 studies on the registry; none are open to participants now.
43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline: 1 open now, 4 under way, none of them phase 3. Of 36 finished, 26 (72%) have results posted.
Among the 43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline, this one is the 3rd largest by enrollment of the 36 interventional ones that give a count, is one of 4 that started in 2011, is one of 10 in phase 3, and was the 11th registered.
GlaxoSmithKline’s Lupus Erythematosus, Systemic studies by the year they started, since 2002.
2 of the studies testing belimumab in Lupus Erythematosus, Systemic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07340463Nanjing University School of MedicineThe Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment | 2027-06 |
| NCT06411249GlaxoSmithKlineA Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) | 2027-06-29 |
Add all 2 to your calendar (.ics) → With an account.
Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, from their registry updates:
Among GlaxoSmithKline’s 43 in Lupus Erythematosus, Systemic:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy, safety and tolerability of belimumab administered subcutaneously (SC) to adult subjects with Systemic Lupus Erythematosus (SLE).
This is a Phase 3, multi-center, international, randomized, double-blind, placebo-controlled, 52-week study to evaluate the efficacy, safety and tolerability of belimumab administered subcutaneously (SC) (200 mg weekly) in adult subjects with active Systemic Lupus Erythematosus (SLE). Approximately 816 SLE subjects will be randomized, with a target of about 544 subjects receiving belimumab and 272 subjects receiving placebo. Subjects completing the 52-week double-blind period can enter a 6-month open-label extension in which all subjects receive belimumab 200 mg SC weekly.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo SC plus standard therapy; placebo administered on Day 0 and then weekly (ie, every 7 days) through Week 51, with final evaluation at Week 52 in the double-blind period. In the open-label extension period, placebo subjects who opt to participate will receive belimumab 200 mg SC weekly for an additional 6-months.
Biological: Placebo · Drug: Standard therapy
Belimumab 200 mg SC plus standard therapy; belimumab administered on Day 0 and then weekly (ie, every 7 days) through Week 51, with a final evaluation at Week 52 in the double-blind period. In the open-label extension period, subjects who opt to participate will continue on the same dose of belimumab for an additional 6-months.
Biological: Belimumab 200 mg SC · Drug: Standard therapy
Placebo
Belimumab 200 mg SC
Also known as: BENLYSTA™
Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.
Percentage of Par. Achieving a SLE Responder Index (SRI) Response Rate at Week 52
SRI response is defined as \>=4 point reduction, from Baseline in safety of estrogen in lupus national assessment (SELENA) systemic lupus erythematosus disease activity index (SLEDAI) score, no worsening (increase of \<0.30 points from Baseline) in physician's global assessment (PGA) and no new British Isles Lupus Assessment Group of SLE clinics (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with Baseline. Analysis was performed using a logistic regression model for the comparison between belimumab and placebo with covariates treatment group, Baseline SELENA SLEDAI score (\<=9 vs. \>=10), Baseline complement levels (low C3 and/or C4 vs. no low C3 or C4) and race (black vs. other).
Time frame: Week 52
Time to First Severe Flare (as Measured by the Modified SLE Flare Index)
Time to first severe SLE flare is defined as the number of days from treatment start date until the participant met an event (event date - treatment start date +1). Analyses of severe SLE flare was performed on modified SELENA SLEDAI SLE flare index that excludes severe flares that were triggered only by an increase in SELENA SLEDAI score to \>12 (since this may only represent a modest increase in disease activity). Only post-baseline severe flares were considered.
Time frame: Baseline (Day 0, prior to dosing) to Week 52
Percentage of Par. Whose Average Prednisone Dose Had Been Reduced by >=25% From Baseline to <=7.5 mg/Day During Weeks 40 Through 52 in Par. Receiving Greater Than 7.5 mg/Day at Baseline
For the analysis of steroid use, all steroid dosages were converted to a prednisone equivalent in mg. The average daily prednisone dose was calculated taking into account all steroids taken intravenously, intramuscularly, SC, intradermally and orally for both SLE and non-SLE reasons. A responder was defined as having a prednisone reduction by \>=25% from Baseline to \<=7.5 mg/day during Weeks 40 through 52. At Baseline, the average daily prednisone dose was the sum of all prednisone doses over 7 consecutive days up to, but not including Day 0, divided by 7. For this analysis, the average prednisone dose was the total prednisone dose during weeks 40 through 52 divided by the number of days during Weeks 40 through 52. Analysis was performed using a logistic regression model with covariates treatment group, Baseline prednisone dose, Baseline SELENA SLEDAI score, (\<=9 vs \>=10), Baseline complement levels (low C3 and/or C4 vs. no low C3 or C4) and race (black vs. other).
Time frame: Baseline (Day 0, prior to dosing), Weeks 40 through Week 52
Participants (Par.) with active systemic lupus erythematosus (SLE) and who were on appropriate stable standard SLE therapy for a period of at least 30 days prior to Day 0 before entering the study were eligible for participation in the study.
| Milestone | Placebo SC | Belimumab 200 mg SC | Open-Label - Placebo SC to Belimumab 200 mg SC | Open-Label - Belimumab 200 SC to Belimumab 200 mg SC |
|---|---|---|---|---|
| Started | 280 | 556 | 0 | 0 |
| Completed | 214 | 463 | 0 | 0 |
| Not completed | 66 | 93 | 0 | 0 |
| Withdrew: Protocol violation | 3 | 4 | 0 | 0 |
| Withdrew: Physician decision | 5 | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 10 | 15 | 0 | 0 |
| Withdrew: Adverse event | 25 | 40 | 0 | 0 |
| Withdrew: Withdrawal by subject | 15 | 12 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 6 | 0 | 0 |
| Withdrew: Positive pregnancy | 1 | 6 | 0 | 0 |
| Withdrew: Treatment failure | 3 | 6 | 0 | 0 |
| Withdrew: Lack of compliance | 2 | 1 | 0 | 0 |
| Withdrew: Unable to visit site | 0 | 2 | 0 | 0 |
| Milestone | Placebo SC | Belimumab 200 mg SC | Open-Label - Placebo SC to Belimumab 200 mg SC | Open-Label - Belimumab 200 SC to Belimumab 200 mg SC |
|---|---|---|---|---|
| Started | 0 | 0 | 206 | 456 |
| Completed | 0 | 0 | 191 | 434 |
| Not completed | 0 | 0 | 15 | 22 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 | 3 |
| Withdrew: Adverse event | 0 | 0 | 5 | 13 |
| Withdrew: Other | 0 | 0 | 9 | 6 |
SRI response is defined as \>=4 point reduction, from Baseline in safety of estrogen in lupus national assessment (SELENA) systemic lupus erythematosus disease activity index (SLEDAI) score, no worsening (increase of \<0.30 points from Baseline) in physician's global assessment (PGA) and no new British Isles Lupus Assessment Group of SLE clinics (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with Baseline. Analysis was performed using a logistic regression model for the comparison between belimumab and placebo with covariates treatment group, Baseline SELENA SLEDAI score (\<=9 vs. \>=10), Baseline complement levels (low C3 and/or C4 vs. no low C3 or C4) and race (black vs. other).
| Percentage of par. | Placebo SC | Belimumab 200 mg SC |
|---|---|---|
| Percentage of Par. Achieving a SLE Responder Index (SRI) Response Rate at Week 52 | 48.4 | 61.4 |
Time to first severe SLE flare is defined as the number of days from treatment start date until the participant met an event (event date - treatment start date +1). Analyses of severe SLE flare was performed on modified SELENA SLEDAI SLE flare index that excludes severe flares that were triggered only by an increase in SELENA SLEDAI score to \>12 (since this may only represent a modest increase in disease activity). Only post-baseline severe flares were considered.
| Days | Placebo SC | Belimumab 200 mg SC |
|---|---|---|
| Time to First Severe Flare (as Measured by the Modified SLE Flare Index) | 118 (2 to 364) | 171 (5 to 358) |
For the analysis of steroid use, all steroid dosages were converted to a prednisone equivalent in mg. The average daily prednisone dose was calculated taking into account all steroids taken intravenously, intramuscularly, SC, intradermally and orally for both SLE and non-SLE reasons. A responder was defined as having a prednisone reduction by \>=25% from Baseline to \<=7.5 mg/day during Weeks 40 through 52. At Baseline, the average daily prednisone dose was the sum of all prednisone doses over 7 consecutive days up to, but not including Day 0, divided by 7. For this analysis, the average prednisone dose was the total prednisone dose during weeks 40 through 52 divided by the number of days during Weeks 40 through 52. Analysis was performed using a logistic regression model with covariates treatment group, Baseline prednisone dose, Baseline SELENA SLEDAI score, (\<=9 vs \>=10), Baseline complement levels (low C3 and/or C4 vs. no low C3 or C4) and race (black vs. other).
| Percentage of par. | Placebo SC | Belimumab 200 mg SC |
|---|---|---|
| Percentage of Par. Whose Average Prednisone Dose Had Been Reduced by >=25% From Baseline to <=7.5 mg/Day During Weeks 40 Through 52 in Par. Receiving Greater Than 7.5 mg/Day at Baseline | 11.9 | 18.2 |
Collected over Serious adverse events (SAEs) and non-SAEs were collected from start of study drug administration to 51 weeks of treatment period/Exit visit for those par. who withdrew during double-blind treatment, plus another 6 months for open-label treatment period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo SC | 2/280 (0.7%) | 44/280 (15.7%) | 218/280 (77.9%) |
| Belimumab 200 mg SC | 3/556 (0.5%) | 60/556 (10.8%) | 403/556 (72.5%) |
| Open-Label - Placebo SC to Belimumab 200 mg SC | 0/206 (0%) | 14/206 (6.8%) | 42/206 (20.4%) |
| Open-Label - Belimumab 200 SC to Belimumab 200 mg SC | 0/456 (0%) | 25/456 (5.5%) | 78/456 (17.1%) |
| Event | Placebo SC | Belimumab 200 mg SC | Open-Label - Placebo SC to Belimumab 200 mg SC | Open-Label - Belimumab 200 SC to Belimumab 200 mg SC |
|---|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 3/280 | 0/556 | 0/206 | 0/456 |
| Herpes zosterInfections and infestations | 0/280 | 1/556 | 2/206 | 0/456 |
| Abdominal abscessInfections and infestations | 0/280 | 0/556 | 2/206 | 0/456 |
| PneumoniaInfections and infestations | 1/280 | 4/556 | 1/206 | 1/456 |
| Renal failure acuteRenal and urinary disorders | 0/280 | 4/556 | 0/206 | 0/456 |
| CellulitisInfections and infestations | 2/280 | 3/556 | 0/206 | 1/456 |
| Pneumonia bacterialInfections and infestations | 2/280 | 3/556 | 0/206 | 0/456 |
| Nephrotic syndromeRenal and urinary disorders | 2/280 | 0/556 | 1/206 | 0/456 |
| HeadacheNervous system disorders | 2/280 | 0/556 | 0/206 | 0/456 |
| DysphagiaGastrointestinal disorders | 2/280 | 0/556 | 0/206 | 0/456 |
| Event | Placebo SC | Belimumab 200 mg SC | Open-Label - Placebo SC to Belimumab 200 mg SC | Open-Label - Belimumab 200 SC to Belimumab 200 mg SC |
|---|---|---|---|---|
| HeadacheNervous system disorders | 25/280 | 57/556 | 4/206 | 10/456 |
| Viral upper respiratory tract infectionInfections and infestations | 24/280 | 48/556 | 9/206 | 17/456 |
| NasopharyngitisInfections and infestations | 22/280 | 38/556 | 9/206 | 7/456 |
| NauseaGastrointestinal disorders | 22/280 | 38/556 | 1/206 | 5/456 |
| Urinary tract infection bacterialInfections and infestations | 18/280 | 41/556 | 2/206 | 14/456 |
| InsomniaPsychiatric disorders | 20/280 | 18/556 | 0/206 | 1/456 |
| CoughRespiratory, thoracic and mediastinal disorders | 19/280 | 22/556 | 1/206 | 8/456 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 11/280 | 31/556 | 6/206 | 11/456 |
| Upper respiratory tract infection bacterialInfections and infestations | 14/280 | 30/556 | 3/206 | 9/456 |
| Back painMusculoskeletal and connective tissue disorders | 15/280 | 28/556 | 4/206 | 5/456 |
| Age, Continuous(Years) | Placebo SC | Belimumab 200 mg SC | Total |
|---|---|---|---|
| Mean | 39.6 ± 12.61 | 38.1 ± 12.10 | 38.6 ± 12.29 |
| Sex: Female, Male(Participants) | Placebo SC | Belimumab 200 mg SC | Total |
|---|---|---|---|
| Female | 268 | 521 | 789 |
| Male | 12 | 35 | 47 |
| Race/Ethnicity, Customized(participants) | Placebo SC | Belimumab 200 mg SC | Total |
|---|---|---|---|
| White/Caucasian/European Heritage | 160 | 326 | 486 |
| Middle East/North African Heritage | 6 | 10 | 16 |
| Central Asian Heritage | 0 | 2 | 2 |
| East Asian Heritage | 15 | 29 | 44 |
| Japanese Heritage | 16 | 13 | 29 |
| South Asian Heritage | 0 | 2 | 2 |
| Southeast Asian Heritage | 32 | 73 | 105 |
| African American/African Heritage | 30 | 56 | 86 |
| American Indian or Alaska Native | 21 | 43 | 64 |
| Native Hawaiian or Other Pacific Islander | 0 | 2 | 2 |
Showing the first 100 of 207 sites across 31 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Nov 2011, a primary completion of Feb 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2017, 2 years 5 months after primary completion. A results delay was requested in Jun 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belimumab
Lupus Erythematosus, Systemic →
Human Genome Sciences Inc., a GSK Company →